In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $42.00. The company's shares closed last Monday at $9.88, close to its 52-week low of $7.13. According to TipRanks.com, Selvaraju 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -41.3% and a 14.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Oncternal Therapeutics. Currently, the analyst consensus on Anavex Life Sciences is a Strong Buy with an average price target of $35.
https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-anavex-life-sciences-avxl?utm_source=advfn.com&utm_medium=referral
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Anavex Life Sciences Charts.